1618648-07-9

Upstream product

• 16473-35-1 4-(hydroxymethyl)benzyl chloride 
• 142-08-5 2-hydroxypyridin 
• 1564668-60-5 1-{[4-(hydroxymethyl)phenyl]methyl}-1,2-dihydropyridin-2-one 
• 623-24-5 1,4-bis(bromomethyl)benzene 
• 1144106-67-1 1-(azidomethyl)-4-(bromomethyl)benzene 

Downstream Products

• 1665276-15-2 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 4-aminomethylbenzylamide hydrochloride 
• 1618648-09-1 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)benzyl]-1H-[1,2,3]triazole-4-carboxylic acid 
• 1618648-10-4 {4-[({1-[4-(2-oxo-2H-pyridin-1-ylmethyl)benzyl]-1H-[1,2,3]triazole-4-carbonyl}amino)-5-methyl]benzyl}carbamic acid tert-butyl ester 
• 1618648-08-0 1-[4-(2-oxo-2H-pyridin-1-ylmethyl)benzyl]-1H-[1,2,3]triazole-4-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Enhanced Efficacy of Gefitinib in Drug-Sensitive and Drug-Resistant Cancer Cell Lines after Arming with a Singlet Oxygen Releasing Moiety

Attractive results have been achieved with small-molecule target-based drugs in the anticancer field; however, enhancing their treatment effect and solving the problem of drug resistance remain key concerns worldwide. Inspired by the specific affinity of

Epidermal Growth Factor Receptor-Targeted Delivery of a Singlet-Oxygen Sensitizer with Thermal Controlled Release for Efficient Anticancer Therapy

Photodynamic therapy (PDT) utilizing light-induced singlet oxygen has achieved attractive results in anticancer fields; however, its development is hindered by limited light penetration depth, skin phototoxicity, tumor hypoxia, and PDT-induced hypoxia. In

Endoperoxide of controlled release singlet oxygen and preparation method and application thereof

The invention discloses endoperoxide of controlled release singlet oxygen and a preparation method and application thereof. The endoperoxide takes 1, 4-di (bromomethyl) benzene as an original raw material, and 1-(nitrine methyl)-4 (bromomethyl) benzene an

BENZYLAMINE DERIVATIVES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

HETEROCYCLIC DERIVATES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.